Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mannose 6-phosphate (M6P) is a crucial biological molecule that serves as a targeting signal for lysosomal hydrolases, facilitating their delivery to lysosomes. This process is primarily mediated by mannose 6-phosphate receptors (MPRs), including the cation-independent mannose 6-phosphate receptor (CI-MPR or CIM6P/IGF2R) and the cation-dependent mannose 6-phosphate receptor (CD-MPR). Dysregulation of M6P signaling and its receptors is implicated in various diseases, such as lysosomal storage disorders like Mucolipidosis type II (MLII) and Mannose 6-phosphate isomerase deficiency (MPI-CDG), as well as conditions like Sonic hedgehog medulloblastoma, Angelman syndrome, hepatic senescence, liver fibrosis, and melanoma. Therapeutic strategies often involve modulating the M6P pathway, targeting its receptors, or administering related compounds like D-mannose or prodrugs such as PMP1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mannose 6-phosphate.